Research Projects & Grants

For Profit Organization

  • A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class Ill Heart Failure Patients (PROACTIVE- HF Trial), Role: Investigator, Endotronix, Inc., (01/2025 - 01/2026) Status: Approved
  • A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patients, Role: Investigator, Novartis Pharmaceuticals Corporation, (10/2016 - 10/2017) Status: Completed
  • Berlin heart excor pediatric ventricular assist device post approval study, Role: Investigator, Berlin Heart Inc., (03/2015 - 03/2016) Status: Completed
  • A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy - Protocol Number: CKI-301, Role: Investigator, NovaCardia, (12/2008 - 12/2009) Status: Completed
  • A placebo-controlled, double-blind, parallel arm trial to assess the efficacay of dronedarone 400mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter (AF/AFL)-Protocol No.:EFC5555, Role: Investigator, Sanofi-Synthelabo Pharmaceuticals, (09/2007 - 09/2008) Status: Completed
  • Follow-up serial infusions of Natrecor® (nesiritide) for the management of patients with heart failure - fusion II Protocol No. A034, Role: Investigator, Scios, Inc., (12/2006 - 12/2007) Status: Completed
  • Multicenter, randomized, double-blind, placebo controlled study to evaluate the long term efficacy and safety of Oral Tolvaptan tablets in subjects hospitalized with worsening congestive heart failure (Protocol #156-03-236), Role: Investigator, Otsuka Pharmaceuticals, (10/2006 - 10/2007) Status: Completed
  • Bio Z data for algorithm improvement, Role: PI, CardioDynamics, (10/2005 - 10/2006) Status: Completed
  • A multi-center, randomized, double-blind, parallel group, placebo-controlled study to assess the effects of Vasogen's Immune Modulation Therapy (IMT) on mortality and morbidity in patients with chronic heart failure - (ACCLAIM) Protocol 0202, Role: Investigator, Vasogen, Inc., (07/2005 - 07/2006) Status: Completed
  • A double-blinded, randomized, placebo-controlled, multicenter study to evaluate the effects of treatment with 2 regimens of subcutaneous (SC) darbepoetin alfa (weight-based dosing and fixed dosing) on hemoglobin concentration response in subjects with symptomatic congestive heart failure (CHF) and anaemia - Protocol No. 20020171, Role: PI, Amgen, Inc., (04/2005 - 04/2006) Status: Completed
  • A pilot study of the renal and systemic hemodynamic effects of nesiritide (human recombinant B-type natriuretic peptide) delivered via bilateral intra-renal infusion in patients with cardiac transplant, Role: Investigator, Flow Medica, Inc., (03/2005 - 03/2006) Status: Completed
  • A double-blind, randomized, placebo-controlled, multicenter study to assess the impact of subcutaneous darbepoetin alfa treatment on exercise tolerance in subjects with symptomatic congestive heart failure and anemia. Protocol No. 20010170 STAMINA-HeFT (Study of Anemia in Heart Failure - Heart Failure Trial), Role: PI, Amgen, Inc., (12/2004 - 12/2005) Status: Completed
  • Multi-center, randomized, double-blind, placebo-controlled study to evaluate the effect of single oral Tolvaptan tablets on hemodynamic parameters in subjects with heart failure, protocol no. 156-04-247, Role: Investigator, Otsuka Maryland Research Institute, (11/2004 - 11/2005) Status: Completed
  • An open, nonrandomized comparison of pharmacokinetic profiles of carvedilol (SK&F 105517) MR and IR on repeat dosing in chronic CHF patients and survivors of an acute MI with LVD - Protocol No.105517, Role: Investigator, GlaxoSmithKline, (10/2004 - 10/2005) Status: Completed

Internal

  • Pediatric heart transplant study group collaborative database, Role: Investigator, LLU Dept. of Pediatrics, (03/2025 - 03/2026) Status: Approved
  • Database for patients enrolled in the cardiomyopathy clinic, Role: PI, LLU Dept. of Medicine, (08/2022 - 08/2023) Status: Completed
  • Pilot investigation using HCV positive heart grafts in HCV negative or previously successfully treated recipients, Role: Investigator, LLU Dept. of Medicine, (06/2021 - 06/2022) Status: Completed
  • Peripheral Arterial Disease Questionnaire, Role: Investigator, LLU Dept. of Medicine, (03/2021) Status: Approved
  • Evaluation of clinical impact of non-invasive hemodynamic monitoring to optimize preventive care of heart failure patients, Role: Investigator, LLU Dept. of Anesthesiology, (09/2020 - 09/2021) Status: Completed
  • Morbidity and mortality associated with the current practice of inotrope administration in CCU, Role: Investigator, LLU Dept. of Medicine, (02/2019) Status: Approved
  • Outcomes of heart failure in adult patients with muscular dystrophy: A single center experience, Role: Investigator, LLU Dept. of Cardiology, (02/2019) Status: Approved
  • Systolic dysfunction following liver transplantation, Role: Investigator, LLU Dept. of Medicine, (03/2016) Status: Completed
  • INTERMACS: Integral registry of mechanically assisted circulatory support, Role: Investigator, LLU Dept. of Surgery (Cardiothoracic), (11/2015 - 11/2016) Status: Completed
  • Evaluation of treating elevated pulmonary arterial pressures with phosphodiesterase-5 inhibitors in patients with left ventricular assist device, Role: Investigator, LLU Dept. of Pharmacy Practice, (11/2015 - 11/2016) Status: Completed
  • Performance of the emotion thermometers tool against DSM-IV-TR-defined depression in cardiovascular settings, Role: Investigator, LLU Dept. of Medicine, (06/2010 - 06/2011) Status: Completed
  • Does biofeedback improve heart rate variability in known New York Heart Association Class I-III heart failure?, Role: Investigator, LLU Dept. of Psychiatry, (07/2006 - 07/2007) Status: Completed
  • Long-term outcomes in responders versus non-responders to beta blockers, Role: PI, LLU Dept. of Cardiology, (03/2006 - 03/2007) Status: Completed
  • B-type natriuretic peptide and prognosis in congestive heart failure, Role: Investigator, LLU School of Medicine, (02/2005 - 02/2006) Status: Completed

Non-Profit Organization

  • Pain assessment, incidence and nature in heart failure (PAIN-HF), Role: Investigator, Mayday Fund, (05/2007 - 05/2008) Status: Completed
  • COMPASS-HF (Chronicle® Offers Management to Patients with Advanced Signs & Symptoms of Heart Failure), Role: Investigator, Medtronic Foundation, (06/2005 - 06/2006) Status: Completed